Evidence map›Paper›PMID 34532268›Full record

ArticleTranslational andrology and urology2021

Combination therapy with curcumin plus tamsulosin and finasteride in the treatment of men with benign prostatic hyperplasia: a single center, randomized control study.

Jing Qiao, Yu Gan, Yuchen Gong, Qingtian Song, Bo Zhang, Bingsheng Li, Feng Ru, Yang Li, Yao He

Open access · diamondAbstract read
In one paragraph

Article in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Efficacy of 1-Year CavacurminJournal of clinical medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jing QiaoDepartment of Ophthalmology, Hunan Children's Hospital, Changsha, China.
Yu GanDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Yuchen GongDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Qingtian SongDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Bo ZhangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Bingsheng LiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Feng RuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Yang LiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Yao HeDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CNHunan Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo perform a prospective, randomized, single center study to investigate the efficacy of combined use of curcumin, an anti-inflammatory agent, with the best standard management (BSM, tamsulosin and finasteride) in benign prostatic hyperplasia (BPH) patients.

methodsOne hundred and twenty-two consecutive patients were randomized to receive tamsulosin 0.2 mg, finasteride 5 mg, and curcumin 2,250 mg once a day (curcumin + BSM group, n=61) versus tamsulosin 0.2 mg, finasteride 5 mg, and placebo (BSM group, n=61) for 6 months. The safety of treatments and their efficacy on improving waist circumference (WC), periprostatic fat thickness (PPFT), lower urinary tract symptoms (LUTS), and sexual function were assessed at baseline and month 6.

resultsOne hundred and sixteen patients completed the whole procedure (116/122, 95.1%). There were significant improvements in prostate volume (PV), maximum flow rate (Qmax), the International Prostate Symptom Score (IPSS), IPSS-voiding subscore (IPSS-V), IPSS-storage subscore (IPSS-S), and quality of life (QoL) from baseline after treatment in both groups. Additionally, both WC and PPFT decreased significantly after treatments than those at baseline in the curcumin + BSM group. Also, WC and PPFT in the curcumin + BSM group were significantly lower than those in the BSM group. In addition, IPSS-S, QoL score, and the 5-item version of the International Index of Erectile Function (IIEF-5) in the curcumin + BSM group improved significantly compared with those in the BSM group.

conclusionsWe conclude that curcumin combined with tamsulosin and finasteride has more beneficial effects in reducing PPFT, protecting erectile function, improving urinary retention symptoms, and QoL scores in BPH patients compared to tamsulosin and finasteride alone.

trial registrationChinese Clinical Trial Registry ChiCTR2100043800.

Indexed as

benign prostatic hyperplasia (BPH)Curcuminlower urinary tract symptoms (LUTS)periprostatic fat thickness (PPFT)

Identifiers

PMID34532268
PMCPMC8421839
OpenAlexW3190842403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.